PRESENTATION

Q3 2024 — Results presentation

Q3 2024PDF · 23 pages3.6 MB


-- 1 of 23 --



-- 2 of 23 --



-- 3 of 23 --



-- 4 of 23 --



-- 5 of 23 --



-- 6 of 23 --



-- 7 of 23 --



-- 8 of 23 --



-- 9 of 23 --

■ ■
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

-- 10 of 23 --

•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
■ ■

-- 11 of 23 --



-- 12 of 23 --



-- 13 of 23 --



-- 14 of 23 --



-- 15 of 23 --



-- 16 of 23 --



-- 17 of 23 --



-- 18 of 23 --



-- 19 of 23 --

•
•
•
•
•
•
•
•
•
•
•

-- 20 of 23 --



-- 21 of 23 --



-- 22 of 23 --

= Achieved
POTENTIAL APPROVALS US/EU 	PLANNED SUBMISSIONS US/EU 	POTENTIAL CLINICAL DATA
Sum of Check Change 	Sum of Check Change 	Sum of Check Change	Phase III
OPSUMIT (macitentan) 	P US OPSUMIT (macitentan) 	US SIMPONI (golimumab) 	P TREMFYA (guselkumab)
P EU Pediatric Pulmonary Arterial Hypertension
(TOMORROW)
Pediatric Pulmonary Arterial Hypertension
(TOMORROW)
EU Pediatric Ulcerative Colitis 	Crohn's Disease (GALAXI)
P US OPSYNVI (macitentan/tadalafil STCT) 	UPTRAVI (selexipag) 	STELARA (ustekinumab) 	P TREMFYA (guselkumab)
P EU Pulmonary Arterial Hypertension 	P EU Pediatric Pulmonary Arterial Hypertension (SALTO) 	P EU Pediatric Crohn's Disease 	Ulcerative Colitis (QUASAR)
P US EDURANT (rilpivirine) 	REKAMBYS 	US TREMFYA (guselkumab) 	P RYBREVANT (amivantamab)
P EU HIV pediatric 2-12 year old 	P EU HIV Adolescents 	Pediatric Psoriasis 	Subcutaneous (PALOMA-3)
P US^ BALVERSA (erdafitinib) 	P US nipocalimab 	P US TREMFYA (guselkumab) 	P seltorexant
P EU Urothelial Cancer (THOR) 	P EU
Generalized Myasthenia Gravis
P EU Crohn's Disease (GALAXI) 	Adjunctive treatment for major depressive disorder
with insomnia symptoms
P US DARZALEX (daratumumab) 	P US SPRAVATO (esketamine) monotherapy 	US TREMFYA (guselkumab) 	P nipocalimab
EU Frontline multiple myeloma transplant eligible
(PERSEUS)
Treatment Resistant Depression (TRD4005) 	Pediatric Juvenile Psoriatic Arthritis 	Generalized Myasthenia Gravis
P US CARVYKTI (ciltacabtagene autoleucel) 	P US RYBREVANT (amivantamab) 	P US TREMFYA (guselkumab) 	P TREMFYA (guselkumab)
P EU Relapsed Refractory multiple myeloma w/1-3 PL
(CARTITUDE-4)
P EU Subcutaneous (PALOMA-3) 	P EU Ulcerative Colitis (QUASAR) 	Crohn's Disease Subcutaneous Induction (GRAVITI)
P US RYBREVANT (amivantamab) 	P US DARZALEX (daratumumab) 	US TREMFYA (guselkumab) 	P SPRAVATO (esketamine)
P EU Frontline Non Small Cell Lung Cancer in
combination with chemotherapy (PAPILLON)
P EU Frontline multiple myeloma transplant eligible
(PERSEUS)
Ulcerative Colitis Subcutaneous Induction
(ASTRO)
Treatment Resistant Depression monotherapy
(TRD4005)
P US RYBREVANT 	P US DARZALEX (daratumumab) 	P US TREMFYA (guselkumab) 	DARZALEX (daratumumab)
P EU Non Small Cell Lung Cancer 2L (MARIPOSA-2) 	P EU Frontline multiple myeloma transplant ineligible
(CEPHEUS)
P EU Crohn's Disease Subcutaneous Induction
(GRAVITI)
Amyloidosis (ANDROMEDA)
P US RYBREVANT / LAZCLUZE 	US DARZALEX (daratumumab) 	Phase II
EU Non Small Cell Lung Cancer (MARIPOSA) 	EU Smoldering Multiple Myeloma (AQUILA) 	P nipocalimab
Sjogren's Disease (DAHLIAS)
P US TREMFYA (guselkumab)
Ulcerative Colitis (QUASAR) 	P TAR-200 (RIS/gemcitabine plus cetrelimab)
Non Muscle Invasive Bladder Cancer (SunRISe-1)
Johnson & Johnson Innovative Medicine Pipeline
Key Events in 2024*
*This information is as of October 15, 2024 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information. ^ BALVERSA US Full Approval

-- 23 of 23 --